MetaCap

CytomX Therapeutics Inc. (CTMX)

NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.03-0.02 (-0.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CTMX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$442.55M
EPS (TTM)
-$0.51
52-week range
1.87 – 8.21
Day range
1.97 – 2.16
Volume / Avg
4.87M / 4.27M
Beta
—

52-week range

$1.87$8.21

CTMX stock today

On Nov 20, CTMX ended the session at $2.03, shedding $0.02 (0.98%), versus the S&P 500's 3.70% decline. At this level, CTMX sits near the bottom of its 52-week range of $1.87 to $8.21: 75.3% below the high, set on Mar 16, 2026 and 8.6% above the low. CTMX is down 52.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.7%.

CytomX Therapeutics has posted a net loss over the last twelve months (EPS of -$0.51), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CytomX Therapeutics

Company profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Sean A. McCarthy DPHIL
Headquarters
South San Francisco, CA
Employees
69
IPO year
2015
Website
cytomx.com

Financial highlights

Full financials

In fiscal 2025, CytomX Therapeutics generated $76.2 million in revenue, down 44.8% from fiscal 2024, its first annual decline since 2021. CytomX Therapeutics reported a net loss of $17.4 million, compared with net income of $31.9 million a year earlier. Operating margin was -29.3%.

CytomX Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$76.20M$138.10M$101.21M$53.16M$37.31M
Growth-44.82%+36.45%+90.38%+42.48%-45.47%
Net income$-17.37M$31.87M$-569.00K$-99.32M$-115.87M
EPS (diluted)$-0.15$0.38$-0.01$-1.51$-1.81

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$12.38+509.85%

  • Strong buy 3
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.09 vs $-0.09

CTMX news

All CTMX news

CytomX Therapeutics peers

Health Care sector
CTMX peer companies
CompanyPrice% ChgMarket capCompare
KMDAKamada Ltd.7.74-1.15%$446.85Mvs CTMX
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs CTMX
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs CTMX
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs CTMX
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs CTMX
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs CTMX
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs CTMX
NGNENeurogene Inc.22.15-3.40%$458.53Mvs CTMX

Indexes, lists and sector

CytomX Therapeutics stock FAQ

What is CytomX Therapeutics's stock price today?

CTMX last traded at $2.03 as of Nov 20, 4:00 PM EST, down 0.98% on the day. Prices are delayed at least 15 minutes.

Who is CytomX Therapeutics's CEO?

Dr. Sean A. McCarthy DPHIL is the chief executive officer of CytomX Therapeutics Inc., which has about 69 employees.

What is the CTMX 52-week high?

The 52-week high for CTMX is $8.21 and the 52-week low is $1.87. The stock is currently 75.3% below its high.

Compare CTMX